IS8311A - Samsetningar katepsín K tálma og bisfosfónats tilað meðhöndla meinvarp í beinum, æxlisvöxt og beintap vegna æxlis - Google Patents

Samsetningar katepsín K tálma og bisfosfónats tilað meðhöndla meinvarp í beinum, æxlisvöxt og beintap vegna æxlis

Info

Publication number
IS8311A
IS8311A IS8311A IS8311A IS8311A IS 8311 A IS8311 A IS 8311A IS 8311 A IS8311 A IS 8311A IS 8311 A IS8311 A IS 8311A IS 8311 A IS8311 A IS 8311A
Authority
IS
Iceland
Prior art keywords
bisphosphonate
cathepsin
inhibitors
combinations
tumor growth
Prior art date
Application number
IS8311A
Other languages
English (en)
Inventor
Zimmermann Johann
Goessl Carsten
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8311(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IS8311A publication Critical patent/IS8311A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS8311A 2003-07-21 2006-02-17 Samsetningar katepsín K tálma og bisfosfónats tilað meðhöndla meinvarp í beinum, æxlisvöxt og beintap vegna æxlis IS8311A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48892503P 2003-07-21 2003-07-21
PCT/EP2004/008107 WO2005014006A1 (en) 2003-07-21 2004-07-20 Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss

Publications (1)

Publication Number Publication Date
IS8311A true IS8311A (is) 2006-02-17

Family

ID=34135094

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8311A IS8311A (is) 2003-07-21 2006-02-17 Samsetningar katepsín K tálma og bisfosfónats tilað meðhöndla meinvarp í beinum, æxlisvöxt og beintap vegna æxlis

Country Status (21)

Country Link
US (1) US20060281714A1 (is)
EP (1) EP1651238A1 (is)
JP (1) JP2006528151A (is)
KR (1) KR20060037382A (is)
CN (1) CN100406016C (is)
AR (1) AR045728A1 (is)
AU (1) AU2004262903B2 (is)
BR (1) BRPI0412769A (is)
CA (1) CA2532948A1 (is)
CO (1) CO5680441A2 (is)
EC (1) ECSP066293A (is)
IL (1) IL172913A0 (is)
IS (1) IS8311A (is)
MA (1) MA27925A1 (is)
MX (1) MXPA06000790A (is)
NO (1) NO20060851L (is)
PE (1) PE20050328A1 (is)
RU (1) RU2006105100A (is)
TN (1) TNSN06021A1 (is)
TW (1) TW200510436A (is)
WO (1) WO2005014006A1 (is)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1686995A1 (en) * 2003-11-19 2006-08-09 Novartis AG Use of cathepsin k inhibitors for treating of severe bone loss diseases
GB0427380D0 (en) * 2004-12-14 2005-01-19 Novartis Ag Organic compounds
EP1931994A2 (en) * 2005-09-26 2008-06-18 Novartis AG Molecular markers associated with bone metastasis
JPWO2009054454A1 (ja) * 2007-10-24 2011-03-03 国立大学法人 東京医科歯科大学 カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤
EP3426674A4 (en) 2016-03-09 2019-08-14 Blade Therapeutics, Inc. CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2018009417A1 (en) 2016-07-05 2018-01-11 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
KR20190063473A (ko) 2016-09-28 2019-06-07 블레이드 테라퓨틱스, 인크. 칼페인 조정자 및 그 치료학적 용도
US20210298890A1 (en) 2018-06-27 2021-09-30 Cirlo Gmbh Implants for recruiting and removing circulating tumor cells
WO2021122803A2 (en) 2019-12-17 2021-06-24 Cirlo Gmbh Tubular shaped elongated catheter device assemblies for interacting with components of bodily fluids, method for recovering cells, cell aggregates and exosomes from a tubular shaped elongated catheter device and smart tubular shaped elongated catheter device assemblies for monitoring interaction with components of bodily fluids
US20250281518A1 (en) * 2022-04-27 2025-09-11 The Regents Of The University Of California Methods and agents for preventing skeletal aging, osteoporosis and obesity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5501969A (en) * 1994-03-08 1996-03-26 Human Genome Sciences, Inc. Human osteoclast-derived cathepsin
US6544767B1 (en) * 1994-10-27 2003-04-08 Axys Pharmaceuticals, Inc. Cathespin O2 protease
US6017926A (en) * 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
WO2000006169A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
US5998390A (en) * 1998-09-28 1999-12-07 The Research Foundation Of State University Of New York Combination of bisphosphonate and tetracycline
WO2000055124A2 (en) * 1999-03-15 2000-09-21 Axys Pharmaceuticals, Inc. Novel compounds and compositions as protease inhibitors
PT1178810E (pt) * 1999-05-21 2005-08-31 Novartis Ag Utilizacao de acidos bisfosfonicos para o tratamento de angiogenese
GB0003111D0 (en) * 2000-02-10 2000-03-29 Novartis Ag Organic compounds
US6468559B1 (en) * 2000-04-28 2002-10-22 Lipocine, Inc. Enteric coated formulation of bishosphonic acid compounds and associated therapeutic methods
AR036375A1 (es) * 2001-08-30 2004-09-01 Novartis Ag Compuestos pirrolo [2,3-d] pirimidina -2- carbonitrilo, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de medicamentos
US7371747B2 (en) * 2001-11-13 2008-05-13 Merck Frosst Canada & Co. Cyanoalkylamino derivatives as protease inhibitors

Also Published As

Publication number Publication date
PE20050328A1 (es) 2005-06-16
MXPA06000790A (es) 2006-04-07
IL172913A0 (en) 2006-06-11
TW200510436A (en) 2005-03-16
TNSN06021A1 (en) 2007-10-03
US20060281714A1 (en) 2006-12-14
NO20060851L (no) 2006-04-21
CN1826124A (zh) 2006-08-30
WO2005014006A1 (en) 2005-02-17
ECSP066293A (es) 2006-07-28
RU2006105100A (ru) 2007-09-20
BRPI0412769A (pt) 2006-09-26
EP1651238A1 (en) 2006-05-03
AU2004262903A1 (en) 2005-02-17
AU2004262903B2 (en) 2007-08-23
AR045728A1 (es) 2005-11-09
CO5680441A2 (es) 2006-09-29
CA2532948A1 (en) 2005-02-17
KR20060037382A (ko) 2006-05-03
MA27925A1 (fr) 2006-06-01
CN100406016C (zh) 2008-07-30
JP2006528151A (ja) 2006-12-14

Similar Documents

Publication Publication Date Title
ATE395871T1 (de) Marknagel zur behandlung von proximalen oberschenkelknochenbrüchen
DE60105295D1 (de) Chinazolinderivate zur behandlung von tumoren
ATE333463T1 (de) Selektive dipeptidische inhibitoren von kallikrein
IS8913A (is) Afleiður 4-tetrazólýl-4-fenýlpiperidíns til þess að meðhöndla verk
NO20042634L (no) 3-Cyanokinoliner som inhibitorer for EGF-R og HER2-kinaser
EP1458726A4 (en) INHIBITORS OF MITOTIC KINESINE
DE60324805D1 (de) Inhibitoren von tyrosinkinasen
EP1675554A4 (en) GEWEBEABRASIVA
EP1664393A4 (en) PROCESS FOR PROCESSING GALLIUM NITRIDE
PT1562589E (pt) Diaminotriazoles úteis como inibidores de proteína-quinases
DK1648905T3 (da) Inhibitorer for thienopyridin- og furopyridinkinase
DK1542710T3 (da) Fremgangsmåde til konservering af organer og væv
ATE326842T1 (de) Zusammensetzung zur saatgutbehandlung
EP1485116A4 (en) ANGIOTENSIN- (1-7) AND AGONISTS OF ANGIOTENSIN- (1-7) FOR THE INHIBITION OF GROWTH OF CANCER CELLS
EP1660436A4 (en) cathepsin inhibitors
ATE471717T1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
IS8311A (is) Samsetningar katepsín K tálma og bisfosfónats tilað meðhöndla meinvarp í beinum, æxlisvöxt og beintap vegna æxlis
EP1651599A4 (en) TYROSINE KINASE INHIBITORS
DE60203207D1 (de) Zange zur orthodontischen Behandlung
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DK1606288T3 (da) Benzensulfonamidderivater, fremgangsmåde til fremstilling deraf og deres anvendelse til behandling af smerte
DK1485345T3 (da) Urokinaseinhibitorer, deres fremstilling og anvendelse
PL1653982T3 (pl) Leczenie halitozy
DE60223707D1 (de) Calcium-l-threonat zur behandlung von knochenfrakturen
EP1658274A4 (en) INHIBITORS OF CATHEPSIN S